Protalix BioTherapeutics Is A Strong Buy With Increasing Revenues And A Promising Pipeline

Protalix BioTherapeutics ( PLX ) is a biotechnology company with two marketed therapies: Elelyso, for Gaucher disease, and Elfabrio for Fabry Disease. As well, the company is actively developing a clinical pipeline that, in our view, may open upAnalyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in PLX over the next ...